Become a donor or member and support our work to advance access to medicines. For everyone. Everywhere
2016
2015
HAI/WHO Pharmaceutical Promotion Manual Still Key to Combating Promotion around the World
HAI Holds Workshops on EU Medicines Policy & Access to Medicines in Eastern Europe
HAI urges MEPs to support key amendments to TTIP resolution
The EU-US Trade Deal Could Leave Europeans Sick
2014
More work needed on new EMA conflicts of interest policy
EMA policy on clinical data publication a step ahead, but falls short of true potential
Abysmal decisions: Why the EC’s medicinal units shouldn’t be moved to DG Industry
Democracy violation: European Commission rejects citizens’ initiative to stop TTIP and CETA
School's IN for summer: HAI staff and interns inspired by Utrecht University's course on pharmaceutical policy analysis
Setting precedents: EMA must get clinical trial data policy right to truly act in public interest
HAI Europe calls on EMA's Management Board to stand for data transparency
Tamiflu review shows desperate need for full clinical trials data transparency
A new (and improved) model to regulate pharmaceutical promotion
Bayer CEO's callous comments highlight failure of current biomedical innovation model
2013
When politicians go to the movies
2011
DG Trade State of Play reveals EU's ambitions for IP protection in FTAs
European drug regulator challenged over revolving door case involving former Director
Corporate funding linked to EU patient & consumer groups policy
2010